[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544618":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":19,"interventions":25,"overallOfficials":13,"centralContacts":13,"locations":13,"responsibleParty":30,"collaborators":13,"id":32,"slug":13,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":27,"eligibilityCriteria":36,"healthyVolunteers":33,"sex":37,"minAge":38,"maxAge":13,"enrollmentInfo":39,"targetDuration":13,"studyType":42,"phases":43,"briefSummary":44,"conditions":45,"keywords":13,"overallStatus":47,"whyStopped":13,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":13},{"fullName":5,"class":6},"CerbaXpert","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Frequency of placental transfer of self-Ab directed against IFN alpha from mother to newborn.","A placental transfer will be defined by the presence of anti-IFN alpha IgG auto Ab in the blood.\n\nof the umbilical cord. The transfer frequency will be calculated with its overall 95% confidence interval and by pathology (lupus, severe COVID-19, myasthenia gravis, incontinentia pigmenti, hypoparathyroidism, adrenal insufficiency, diffuse candidiasis, Biermer's disease, dysthyroidism, type 1 diabetes, celiac disease, autoimmune thyroid disease such such as Graves' disease, Hashimoto's thyroiditis), in HIV-positive women by pathology (lupus, severe COVID-19, myasthenia gravis, incontinentia pigmenti, hypoparathyroidism, adrenal insufficiency, diffuse candidiasis, Biermer's disease, dysthyroidism, type 1 diabetes, celiac disease, autoimmune thyroid disease such as Graves' disease, Hashimoto's thyroiditis), in HIV-positive women.","30 months",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":6,"observationalModel":13,"timePerspective":13,"maskingInfo":17},"NA","SINGLE_GROUP",{"masking":18,"maskingDescription":13,"whoMasked":13},"NONE",[20],{"label":21,"type":6,"description":22,"interventionNames":23},"pregnant women","Pregnant woman over 18 years old\n\n\\- Woman whose gestational age is less than 30 weeks",[24],"Other: Pregiferon",[26],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":13},"Pregiferon","This Study aims to study the transmission of anti-interferon alpha autoantibodies from mother to child viaplacental barrier",[21],{"type":31,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100544618",false,"NCT06371235","Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier","Inclusion Criteria:\n\n* Pregnant woman over 18 years old\n* Woman whose gestational age is less than 30 weeks.\n* Having agreed to carry out an assay of anti-IFN alpha IgG auto-Ac before 30 weeks\n* Give birth in the inclusion center\n* Suffering from a pathology frequently associated with the presence of these anti-autoantibodies IFN alpha (lupus, severe COVID-19, myasthenia gravis, incontinentia pigmenti, hypoparathyroidism, adrenal insufficiency, diffuse candidiasis, Biermer's disease, dysthyroidism, type 1 diabetes, celiac disease, auto-thyroid disease immune system such as Graves' disease, Hashimoto's thyroiditis) or knowing its positive anti-IFN alpha autoantibody status\n* Affiliated with the Social Security system\n\nExclusion Criteria:\n\n* Patient who underwent a blood transfusion less than 2 months ago\n* Patient who received an organ transplant\n* Patient undergoing immunotherapy, stem cell therapy and\u002For other malignancy maternal, under heavy treatment (chemotherapy) less than 6 months before inclusion","FEMALE","18 Years",{"count":40,"type":41},250,"ESTIMATED","INTERVENTIONAL",[15],"The main objective of the study is to evaluate the frequency of placental transfer of self-Ab directed against the mother's IFN alpha in the newborn, in all women suffering from a pathology frequently associated with the presence of these autoantibodies and in those seropositive during the pregnancy.",[46],"Woman Suffering From a Pathology Frequently Associated With the Presence of These Anti-autoantibodies Type-I Interferons","NOT_YET_RECRUITING","2024-04-12",{"date":50,"type":51},"2024-04-17","ACTUAL",{"date":53,"type":41},"2024-09",{"date":55,"type":41},"2027-03",{"name":5,"class":6}]